Prasad Raju's Form 4 filing
CRISPR Therapeutics AG (CRSP) · filed Mar 17, 2026
- Accession no.
- 0001193125-26-111284
- Filed
- Mar 17, 2026
- Trade date
- Mar 14-16, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $476.3K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Prasad RajuCIK 0001968317 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 14, 2026 | Common Shares | MOption exerciseAcquired | +10,000 | –F2 | – | 16,767 | Direct | |
| Mar 14, 2026 | Common Shares | MOption exerciseAcquired | +6,875 | –F2 | – | 23,642 | Direct | |
| Mar 16, 2026 | Common Shares | SSaleDisposed | −5,848 | $48.26 | −$282,224.48 | 17,794 | Direct | |
| Mar 16, 2026 | Common Shares | SSaleDisposed | −4,021 | $48.26 | −$194,053.46 | 13,773 | Direct | |
| Mar 16, 2026 | Common Shares | GGiftDisposed | −750 | $0.00 | $0 | 13,023 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
Referenced by the price of 2 transactions in Table I and 2 transactions in Table II.